Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to test the safety and efficacy of two dose regimens of the
complement C5a receptor CCX168 in patients with anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis (AAV).
Funding Source - FDA OOPD